After reviewing data on the risk of agranulocytosis for metamizole, the PRAC concluded that the existing warnings in the product information needed to be updated. The committee recommended that healthcare professionals must inform patients to stop taking these medicines and seek immediate medical attention if they develop symptoms of agranulocytosis.

Product information to be updated to raise awareness of known risk of agranulocytosis and facilitate its early detection and diagnosis.